376 related articles for article (PubMed ID: 27898340)
1. Real world data of 1473 patients treated with ulipristal acetate for uterine fibroids: Premya study results.
Fernandez H; Schmidt T; Powell M; Costa AP; Arriagada P; Thaler C
Eur J Obstet Gynecol Reprod Biol; 2017 Jan; 208():91-96. PubMed ID: 27898340
[TBL] [Abstract][Full Text] [Related]
2. Real-world data of 197 patients treated with ulipristal acetate for uterine fibroids: PREMYA study French population main outcomes.
Fernandez H; Descamps P; Koskas M; Lopès P; Brun JL; Darai E; Agostini A
J Gynecol Obstet Hum Reprod; 2017 Sep; 46(7):559-564. PubMed ID: 28676450
[TBL] [Abstract][Full Text] [Related]
3. Ulipristal acetate for pre-operative management of uterine fibroids: Modeling outcomes and costs.
Badiani B; Chiumente M; Messori A
Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():84-88. PubMed ID: 29408752
[TBL] [Abstract][Full Text] [Related]
4. Single or repeated gonadotropin-releasing hormone agonist treatment avoids hysterectomy in premenopausal women with large symptomatic fibroids with no effects on sexual function.
Perrone AM; Pozzati F; Di Marcoberardino B; Rossi M; Procaccini M; Pellegrini A; Santini D; De Iaco P
J Obstet Gynaecol Res; 2014 Jan; 40(1):117-24. PubMed ID: 24033631
[TBL] [Abstract][Full Text] [Related]
5. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
Pérez-López FR
Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
[TBL] [Abstract][Full Text] [Related]
6. Ulipristal acetate: a novel option for the medical management of symptomatic uterine fibroids.
Talaulikar VS; Manyonda IT
Adv Ther; 2012 Aug; 29(8):655-63. PubMed ID: 22903240
[TBL] [Abstract][Full Text] [Related]
7. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
Talaulikar VS; Manyonda I
Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
[TBL] [Abstract][Full Text] [Related]
8. A multi-centre, randomized, non-inferiority trial to compare ulipristal with standard surgical treatment in women with symptomatic uterine fibroids: Protocol of the MYOMEX-2 trial.
Middelkoop MA; Huirne JAF; van der Weide MCJ; Bosmans JE; Hehenkamp WJK;
Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():63-69. PubMed ID: 33171419
[TBL] [Abstract][Full Text] [Related]
9. Outcome of patients with uterine fibroids after 3-month ulipristal acetate therapy.
Brun JL; Rajaonarison J; Froeliger A; Monseau-Thiburce AC; Randriamboavonjy R; Vogler A
Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():13-18. PubMed ID: 29328939
[TBL] [Abstract][Full Text] [Related]
10. The cost-effectiveness of ulipristal acetate tablets in treating patients with moderate to severe symptoms of uterine fibroids.
Nagy B; Timár G; Józwiak-Hagymásy J; Kovács G; Merész G; Vámossy I; Ágh T; László Á; Vokó Z; Kaló Z
Eur J Obstet Gynecol Reprod Biol; 2014 Apr; 175():75-81. PubMed ID: 24568866
[TBL] [Abstract][Full Text] [Related]
11. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
[TBL] [Abstract][Full Text] [Related]
12. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital.
Woodhead N; Pounds R; Irani S; Pradhan P
J Obstet Gynaecol; 2018 Aug; 38(6):813-817. PubMed ID: 29526144
[TBL] [Abstract][Full Text] [Related]
13. [LAPAROSCOPIC MYOMECTOMY AFTER ULIPRISTAL ACFTATF TRFATMFMT.].
Blagovest B; Magunska N
Akush Ginekol (Sofiia); 2016; 55(5):29-31. PubMed ID: 29790712
[TBL] [Abstract][Full Text] [Related]
14. Ulipristal acetate versus placebo for fibroid treatment before surgery.
Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
[TBL] [Abstract][Full Text] [Related]
15. Long-term medical management of uterine fibroids with ulipristal acetate.
Donnez J; Donnez O; Matule D; Ahrendt HJ; Hudecek R; Zatik J; Kasilovskiene Z; Dumitrascu MC; Fernandez H; Barlow DH; Bouchard P; Fauser BC; Bestel E; Loumaye E
Fertil Steril; 2016 Jan; 105(1):165-173.e4. PubMed ID: 26477496
[TBL] [Abstract][Full Text] [Related]
16. What does non-eligibility for myoma surgery mean in the context of sequential prescription of ulipristal acetate?
Pourcelot AG; Capmas P; Laberge P; Fernandez H
J Gynecol Obstet Hum Reprod; 2020 Apr; 49(4):101688. PubMed ID: 31972353
[TBL] [Abstract][Full Text] [Related]
17. Treatment Choices in a National Cohort of Canadian Women With Symptomatic Uterine Fibroids.
Strand T; Kives S; Leyland N; Ashkenas J; Janiszewski P; Thiel J
J Obstet Gynaecol Can; 2020 Dec; 42(12):1475-1482.e2. PubMed ID: 33046429
[TBL] [Abstract][Full Text] [Related]
18. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
Szamatowicz M; Kotarski J
Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
[TBL] [Abstract][Full Text] [Related]
19. Role of ethnicity in treating uterine fibroids with ulipristal acetate.
Murji A; Crosier R; Chow T; Ye XY; Shirreff L
Fertil Steril; 2016 Oct; 106(5):1165-1169. PubMed ID: 27336213
[TBL] [Abstract][Full Text] [Related]
20. Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids.
Garnock-Jones KP; Duggan ST
Drugs; 2017 Oct; 77(15):1665-1675. PubMed ID: 28900897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
